- My Forums
- Tiger Rant
- LSU Recruiting
- SEC Rant
- Saints Talk
- Pelicans Talk
- More Sports Board
- Fantasy Sports
- Golf Board
- Soccer Board
- O-T Lounge
- Tech Board
- Home/Garden Board
- Outdoor Board
- Health/Fitness Board
- Movie/TV Board
- Book Board
- Music Board
- Political Talk
- Money Talk
- Fark Board
- Gaming Board
- Travel Board
- Food/Drink Board
- Ticket Exchange
- TD Help Board
Customize My Forums- View All Forums
- Show Left Links
- Topic Sort Options
- Trending Topics
- Recent Topics
- Active Topics
Started By
Message
Biotech Drama - Gene Editing
Posted on 8/30/16 at 7:34 am
Posted on 8/30/16 at 7:34 am
Anybody watching this space?
The two big players, Editas and Intellia, are in the middle of a huge multi-institution fight over fundamental CRISPR-Cas9 gene editing IP.
Editas: Harvard/MIT
Intellia: Berkeley
The fight boils down to who was first. Things took an interesting turn two weeks ago when a post-doc who worked in the Harvard/MIT lab during the years in question basically said that they didn't know what they were doing at the time, and basically misled the USPTO when their application was filed.
There are a lot of juicy details to the story, including founders switching sides, disperate IPOs, and huge stock price swings.
EDIT is down 60% since April, with NTLA only down 30%. Both startups had market caps over $1 billion recently, but it looks like investors are afraid to pick a side at this point.
The two big players, Editas and Intellia, are in the middle of a huge multi-institution fight over fundamental CRISPR-Cas9 gene editing IP.
Editas: Harvard/MIT
Intellia: Berkeley
The fight boils down to who was first. Things took an interesting turn two weeks ago when a post-doc who worked in the Harvard/MIT lab during the years in question basically said that they didn't know what they were doing at the time, and basically misled the USPTO when their application was filed.
There are a lot of juicy details to the story, including founders switching sides, disperate IPOs, and huge stock price swings.
EDIT is down 60% since April, with NTLA only down 30%. Both startups had market caps over $1 billion recently, but it looks like investors are afraid to pick a side at this point.
This post was edited on 8/30/16 at 12:06 pm
4
Posted on 8/30/16 at 9:49 am to Sigma
I'm familiar with what's going on. I met Jennifer Doudna, who developed it at Berkeley. I believe her group has the right and my money is on her, but who knows.
This post was edited on 8/30/16 at 10:31 am
Posted on 8/30/16 at 10:28 am to Sigma
Google owns a big piece of editas, i imagine google would have done their homework!
Posted on 8/30/16 at 11:45 am to Sigma
I'm currently invested in Bayer. Feel like that's a good way to get some exposure to this technology without having to put too many eggs in that basket.
https://seekingalpha.com/news/3204469-bayer-crispr-therapeutics-joint-venture-casebia-therapeutics-establishes-operations-boston?source=email_rt_mc_readmore&app=1&dr=1#email_link
quote:
Casebia Therapeutics, the joint venture between Bayer (OTCPK:BAYRY) and gene editing firm CRISPR Therapeutics, will operate out of Cambridge, MA. The site will house 80 employees, mostly in R&D.
The JV was announced in December 2015. Bayer will contribute at least $300M to develop CRISPR/Cas9 gene-editing technology to treat a range of disorders in the blood, cardiovascular area and eyes. Bayer also acquired a majority stake in CRISPR for $35M.
Bayer closed a separate development deal in May with privately held ERS Genomics for gain access to its CRISPR/Cas9 patents for certain applications.
One of the founders of CRISPR Therapeutics was CRISPR/Cas9 discoverer Dr. Emmanuelle Charpentier.
https://seekingalpha.com/news/3204469-bayer-crispr-therapeutics-joint-venture-casebia-therapeutics-establishes-operations-boston?source=email_rt_mc_readmore&app=1&dr=1#email_link
Posted on 8/30/16 at 1:27 pm to Sigma
call me when I take edit my genes to give me 6 pack abs while slamming Taco Bell.
Posted on 8/30/16 at 3:45 pm to Northwestern tiger
quote:
I'm familiar with what's going on. I met Jennifer Doudna, who developed it at Berkeley. I believe her group has the right and my money is on her, but who knows.
I tend to agree. She has always struck me as an honest scientist and been fighting an uphill battle from the start. I just really distrust the Harvard/MIT/Broad machine.
Posted on 8/30/16 at 9:46 pm to dabigfella
Like they did with Glass? Or with Boston Dynamics? Or with Nest? Just because it's Alphabet doesn't make it infallible.
Posted on 8/31/16 at 8:25 am to Jon Ham
quote:
Casebia Therapeutics, the joint venture between Bayer (OTCPK:BAYRY) and gene editing firm CRISPR Therapeutics, will operate out of Cambridge, MA. The site will house 80 employees, mostly in R&D.
CRISPR Therapeutics is probably next in line, since their primary founder (Charpentier) co-published with Doudna early on. I see them as a solid third option. Mello's an advisor, and they do have some Boston flavor as well. Fits with the Casebia venture I suppose.
Do you see CRISPR (the company) like Caribou, basically the IP holder and spinning out therapeutics companies (Intellia & Casebia so far)?
Moderna looks like it's doing the same in the mRNA space. But that's a real head scratcher that probably deserves its own thread.
Page 1 of 1
Popular
Back to top
Follow TigerDroppings for LSU Football News